pyridine-3-carboxamide,hydrochloride

Nicotinamide Hydrochloride is a form of vitamin B3 or niacin that inhibits sirtuin 2 (SIRT2) activity in vitro, with an EC50 of 2 μM. Nicotinamide Hydrochloride inhibits up to 90% melanoma cell number and increases cellular NAD+, ATP, ROS levels. Nicotinamide Hydrochloride inhibts tumor growth in vivo and improves survival of melanoma-bearing mice, which can be used for the research of skin cancers such as melanoma[1].

Signaling Pathways >> Epigenetics >> Sirtuin

Research Areas >> Cancer

Signaling Pathways >> Cell Cycle/DNA Damage >> Sirtuin

Human Endogenous Metabolite

SIRT2:2 μM (EC50)

Nicotinamide Hydrochloride (0-50 mM, 24/48 h ) reduces cell number in a time-dependent and dose-dependent manner in A375 and SK-MEL-28 cells[1]. Nicotinamide Hydrochloride (10-50 mM, 24 h ) makes A375 cells undergo accumulation in G1 phase, reduction in S phase, and increase inthe sub-G1 (apoptosis) phase[1]. Nicotinamide Hydrochloride (1-50 mM, 6 h ) increases NAD+, ATP and ROS levels in A375 and SK-MEL-28 cells[1]. Nicotinamide Hydrochloride (0.01-20 mM, 1 h) inhibits purified SIRT2 enzymatic activity in vitro with an EC50 of 2 μM[1]. Cell Viability Assay[1] Cell Line: A375, SK-MEL-28, mouse B16-F10 cell Concentration: 0, 1, 20, 50 mM Incubation Time: 24 h, 48 h Result: Reduced cell number in a dose-dependent manner with a strong inhibitory effect at 20mM and an almost complete effect at 50 mM. Cell Cycle Analysis[1] Cell Line: A375, SK-MEL-28 Concentration: 10, 20, 50 mM Incubation Time: 24 h Result: Arrested A375 cells in G1 phase.

Nicotinamide Hydrochloride (Intraperitoneal injection, 1500 and 1800 mg/Kg, 5 days per week) inhibits tumor growth in murine metastatic melanoma model[1]. Nicotinamide Hydrochloride (Intraperitoneal injection, 1800 mg/Kg, once a day, murine metastatic melanoma model) affects IFN-γ (a key mediator of cell-mediated anti-tumor immunity), increases the plasma levels of eotaxin and IL-5, reduces the plasma levels of IL-3, IL-12, RANTES and IL-10[1]. Animal Model: C57BL/6 mice (subcutaneous injected with B16-F10 cells)[1] Dosage: 1000, 1500, 1800 mg/Kg. Administration: Intraperitoneal injection, 5 days per week (followed by 2-day rest) or once a day. Result: Inhibited tumor growth at 1500 and 1800 mg/Kg, and had no effect on the body weight. Increased the frequency of IFN-γ producing cells and modulated the protein levels of cytokines and chemokines in the plasma of tumor-bearing mice.

[1]. [1] Francesca Scatozza, et al. Nicotinamide inhibits melanoma in vitro and in vivo. J Exp Clin Cancer Res. 2020 Oct 7;39(1):211.